Quidel (QDEL)’s Insider Douglas Bryant Unloaded 36,000 Shares of the Company; Biospecifics Tech (BSTC) Sellers Increased By 1% Their Shorts

Biospecifics Tech Corp (NASDAQ:BSTC) had an increase of 1% in short interest. BSTC’s SI was 172,000 shares in July as released by FINRA. Its up 1% from 170,300 shares previously. With 27,500 avg volume, 6 days are for Biospecifics Tech Corp (NASDAQ:BSTC)’s short sellers to cover BSTC’s short positions. The SI to Biospecifics Tech Corp’s float is 3.18%. The stock increased 3.29% or $1.43 during the last trading session, reaching $44.86. About 46,004 shares traded or 104.35% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 16.75% since July 1, 2017 and is downtrending. It has underperformed by 29.32% the S&P500. Some Historical BSTC News: 23/04/2018 – PALADIN LABS XIAFLEX NEW INDICATION FOR PEYRONIE’S DISEASE; 13/03/2018 – BIOSPECIFICS COMMENTS ON CCH TRIAL TREATING UTERINE FIBROIDS; 12/03/2018 BioSpecifics Closes Above 50-Day Moving Average: Technicals; 09/05/2018 – BioSpecifics 1Q EPS 54c; 09/05/2018 – BIOSPECIFICS – AS OF MARCH 31, 2018, CO HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $64.2 MLN, COMPARED TO $65.1 MLN AS OF DEC 31, 2017; 13/03/2018 – BIOSPECIFICS: CCH INTERIM PHASE 1 SHOWED SAFETY, EFFECTIVENESS; 24/04/2018 – BioSpecifics Short-Interest Ratio Rises 46% to 9 Days; 23/04/2018 – PALADIN LABS REPORTS LAUNCH OF NEW INDICATION FOR XIAFLEX; 11/04/2018 – Northpointe Capital LLC Exits Position in BioSpecifics; 12/03/2018 – BioSpecifics Technologies Corp

Another recent and important BioSpecifics Technologies Corp. (NASDAQ:BSTC) news was published by Globenewswire.com which published an article titled: “Investor Expectations to Drive Momentum within Capital Product Partners, Nova Measuring Instruments, BioSpecifics …” on June 06, 2018.

Investors sentiment decreased to 0.77 in Q1 2018. Its down 0.45, from 1.22 in 2017Q4. It is negative, as 14 investors sold BioSpecifics Technologies Corp. shares while 29 reduced holdings. 12 funds opened positions while 21 raised stakes. 3.50 million shares or 3.69% less from 3.63 million shares in 2017Q4 were reported. First Manhattan accumulated 26,380 shares. Eagle Asset Management Inc owns 150,217 shares. Pnc Fin Services Group reported 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Manufacturers Life The has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Los Angeles Capital Mgmt & Equity Research Incorporated accumulated 4,859 shares. Clarivest Asset Limited Liability Corporation reported 31,653 shares or 0.02% of all its holdings. Globeflex Capital Lp invested in 4,300 shares. Sei Comm has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Comml Bank Of America De, a North Carolina-based fund reported 721 shares. American Int Inc reported 3,612 shares or 0% of all its holdings. Century Cos holds 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC) or 11,220 shares. Aqr Limited Liability has 114,376 shares. Matarin Cap Management Limited Com, Connecticut-based fund reported 33,780 shares. New York State Common Retirement Fund owns 7,597 shares. 6,117 are held by Smith Asset Mngmt Lp.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $323.63 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 27.52 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Among 8 analysts covering Quidel Corp (NASDAQ:QDEL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quidel Corp has $6400 highest and $52.0 lowest target. $59.80’s average target is -10.08% below currents $66.5 stock price. Quidel Corp had 10 analyst reports since January 2, 2018 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $6400 target in Thursday, April 5 report. Barclays Capital maintained Quidel Corporation (NASDAQ:QDEL) rating on Monday, April 2. Barclays Capital has “Overweight” rating and $63 target. The stock of Quidel Corporation (NASDAQ:QDEL) has “Strong Buy” rating given on Thursday, March 8 by Raymond James. Craig Hallum initiated the stock with “Buy” rating in Monday, March 26 report. The stock has “Buy” rating by Piper Jaffray on Tuesday, April 3. The stock of Quidel Corporation (NASDAQ:QDEL) earned “Buy” rating by Barclays Capital on Monday, January 22. The stock has “Buy” rating by CL King on Thursday, January 4. C.L. King upgraded the shares of QDEL in report on Thursday, January 4 to “Buy” rating. Canaccord Genuity maintained Quidel Corporation (NASDAQ:QDEL) rating on Tuesday, January 2. Canaccord Genuity has “Buy” rating and $52.0 target. The stock of Quidel Corporation (NASDAQ:QDEL) earned “Buy” rating by William Blair on Friday, April 13.

Since January 3, 2018, it had 0 buys, and 11 selling transactions for $15.28 million activity. 12,000 shares were sold by SCHULER JACK W, worth $582,031. Shares for $2.02 million were sold by BRYANT DOUGLAS C on Thursday, April 26. Brown Thomas D had sold 30,451 shares worth $1.87 million on Friday, May 25. On Tuesday, June 12 Kroll Werner sold $165,392 worth of Quidel Corporation (NASDAQ:QDEL) or 2,500 shares. BORKAR RATAN S sold $1.35 million worth of Quidel Corporation (NASDAQ:QDEL) on Wednesday, January 3.

Investors sentiment increased to 1.45 in 2018 Q1. Its up 0.28, from 1.17 in 2017Q4. It improved, as 8 investors sold Quidel Corporation shares while 41 reduced holdings. 32 funds opened positions while 39 raised stakes. 33.10 million shares or 6.99% more from 30.94 million shares in 2017Q4 were reported. Citadel Advsr Lc has 0% invested in Quidel Corporation (NASDAQ:QDEL) for 56,328 shares. Signaturefd Ltd Liability has invested 0.01% in Quidel Corporation (NASDAQ:QDEL). Raymond James Fincl Serv Advisors owns 11,956 shares or 0% of their US portfolio. Sei Investments Company holds 0.02% or 103,499 shares. Paloma Prtn Mgmt Co reported 0.01% in Quidel Corporation (NASDAQ:QDEL). State Street Corporation stated it has 636,763 shares. Illinois-based Balyasny Asset Mngmt Ltd Liability Company has invested 0% in Quidel Corporation (NASDAQ:QDEL). Geode Cap Ltd Llc has 378,445 shares. Prelude Cap Ltd Co has 7,308 shares. Dimensional Fund Advisors Limited Partnership holds 0.02% or 925,055 shares in its portfolio. D E Shaw And Inc has 418,063 shares for 0.03% of their portfolio. Rhumbline Advisers reported 28,581 shares stake. Point72 Asia (Hong Kong) invested in 0.05% or 1,826 shares. Massachusetts Finance Ma, Massachusetts-based fund reported 273,001 shares. Aqr Cap Management Ltd Limited Liability Company owns 16,649 shares or 0% of their US portfolio.

Analysts await Quidel Corporation (NASDAQ:QDEL) to report earnings on July, 25. They expect $0.14 EPS, up 140.00% or $0.49 from last year’s $-0.35 per share. QDEL’s profit will be $5.24M for 118.75 P/E if the $0.14 EPS becomes a reality. After $1.23 actual EPS reported by Quidel Corporation for the previous quarter, Wall Street now forecasts -88.62% negative EPS growth.

The stock increased 0.30% or $0.2 during the last trading session, reaching $66.5. About 197,657 shares traded. Quidel Corporation (NASDAQ:QDEL) has risen 145.59% since July 1, 2017 and is uptrending. It has outperformed by 133.02% the S&P500. Some Historical QDEL News: 18/04/2018 – New Research Coverage Highlights Quidel, Eros International, Hennessy Capital Acquisition Corp. II, United Dominion Realty Trus; 05/03/2018 – QUIDEL GETS FDA CLEARANCE FOR POINT-OF-CARE SOFIA® LYME FLUORES; 25/04/2018 – FDA: Diagnostic Hybrids, Inc.- Quidel MicroVue Intact PTH EIA, Model 8044. An enzyme immunoassay for the quantification of; 08/05/2018 – Quidel 1Q Adj EPS $1.29; 08/05/2018 – QUIDEL 1Q ADJ EPS $1.29, EST. $1.01; 16/05/2018 – Quidel Presenting at UBS Conference May 23; 05/03/2018 – Quidel Receives FDA Clearance For Its Point-of-Care Sofia(R) Lyme Fluorescent Immunoassay For Use With Sofia(R) 2 Instrument; 05/03/2018 quidel corporation | sofia lyme fia, sofia 2 analyzer, sofia | K173691 | 02/28/2018 |; 29/03/2018 – New Research Coverage Highlights Digital Realty Trust, United Dominion Realty Trust, Quidel, Brandywine Realty Trust, Beneficia; 30/04/2018 – MFS New Discovery Fund Adds Quidel, Exits MuleSoft

Another recent and important Quidel Corporation (NASDAQ:QDEL) news was published by Businesswire.com which published an article titled: “Quidel to Present at William Blair 38” on June 05, 2018.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart